Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Mazen Animal Health
company
About
Mazen Animal Health focuses on developing, delivering, and commercializing novel biological vaccines and therapeutics.
- 1 - 10
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Mazen Animal Health is a new company focused on developing, delivering and commercializing novel biological vaccines and therapeutics that disrupt the status quo and address complex or unsolved challenges in animal health and protein production. Their first disruptive solution is a reinvention of vaccines with a novel technology platform that will shift the paradigm in disease prevention.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$11M
Mazen Animal Health has raised a total of
$11M
in funding over 2 rounds. Their latest funding was raised on
May 25, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| May 25, 2022 | Series A | $11M | 3 | — | — | Detail |
| Feb 23, 2021 | Grant | — | 1 |
Iowa G2M Accelerator
|
— | Detail |
| Jan 31, 2019 | Angel | — | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
5
Mazen Animal Health is funded by 5 investors.
Iowa G2M Accelerator
and Innovation In Motion
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Iowa G2M Accelerator
|
Yes | Grant |
|
|
Yes | Angel |
|
|
— | Series A |
|
|
— | Series A |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
